SAN DIEGO, Dec. 22, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP) did not…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
